Lipid A-free polysaccharide (PS) isolated from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide (LPS) was covalently coupled to toxin A via reductive amination. The PS-toxin A conjugate was comprised of 29.8% PS and 70.2% toxin A, possessed a molecular weight of > 1 X 106, was nontoxic for animals and was nonpyrogenic for rabbits at a dose of 50 tg/kg body wt when administered intravenously. The conjugate evoked only mild, transient reactions upon subcutaneous administration to human volunteers. Vaccination engendered immunoglobulin G (IgG) antibody, which neutralized the cytotoxic effect of toxin A and promoted the uptake and killing of P. aeruginosa in the presence of human polymorphonuclear leukocytes. Passively transferred IgG isolated from the serum of immunized donors was far more effective at preventing fatal P. aeruginosa burn wound sepsis than paired preimmunization serum. These studies establish the potential usefulness of such a PS-toxin A conjugate as a vaccine against P. aeruginosa.
Introduction
Gram-negative aerobic bacilli are the leading cause of fatal nosocomial infections (1, 2) . Preeminant among these pathogens is Pseudomonas aeruginosa, whose ability to cause life-threatening infections in compromised patients is well documented (3, 4) . The case fatality rate for P. aeruginosa bacteremia reported in the literature from 1951 to 1981 has remained in the range of 25 to 50% (4, 5) , indicating the limited impact of antibiotic therapy.
The use of immunological means as an adjunct to antimicrobial chemotherapy for the control ofP. aeruginosa infections has recently gained much attention (4, 6) . Human immunity to P. aeruginosa had been found to correlate with humoral antibody directed against serospecific epitopes expressed by LPS and against toxin A (7, 8) . A reduction in fatalities due to P. aeruginosa among compromised patients has been obtained following vaccination with an LPS-based vaccine (9, 10) . However, the high frequency of adverse reactions associated with vaccination has limited its use.
The above findings indicate that optimal protection against P. aeruginosa would be obtained by use of a vaccine capable of eliciting both anti-LPS and anti-toxin A antibody. We have pre-viously demonstrated that serologically active nonimmunogenic O-polysaccharide (0-PS)' derived from LPS could be covalently linked to toxin A, yielding a conjugate vaccine (1 1). This conjugate was found to be nontoxic for animals and capable of evoking both an anti-LPS and an anti-toxin A immune response. We now report on the safety and immunogenicity of an O-PStoxin A conjugate vaccine in humans.
Methods
Purification ofantigens. LPS was purified from P. aeruginosa strain W-18 (immunotype 5) as previously described (12) . The final preparation of LPS contained < 1% (wt/wt) protein or nucleic acid (12) .
PS was obtained from LPS by acid hydrolysis (1 1). Briefly, LPS (suspended in 1% vol/vol acetic acid) was heated for 90 min at 100°C. After cooling, the suspension was centrifuged at 5,000 g for 15 min. The lipid A-containing pellet was discarded and the supernatant extracted three times with chloroform/methanol (3:1). After concentration by rotory evaporation, the aqueous phase was passed over a 5 X 40-cm column of AcA34 (LBK-Produkter, Bromma, Sweden) equilibrated in distilled water. The PS fractions eluting with a relative molecular mass (Mi) . 50,000 were pooled, concentrated, and Iyophilized. Toxin A was purified from the culture supernatants ofP. aeruginosa PA103 as previously described (13). The purity ofthe toxin A preparations as measured by high pressure liquid chromatography (E. I. DuPont Co., Wilmington, DE, GF-250 column) (see below) was 2 96%. The mean lethal dose when administered intraperitoneally to 18-20 g female NMRI mice was between 0.1 and 0.25 gg per mouse.
Synthesis ofPS-toxin A conjugate. The PS-toxin A conjugate was produced essentially as described elsewhere (1 1). Briefly, PS was oxidized by treatment with NaIO4 at 22°C, after which ethylene glycol was added to exhaust residual NaIO4. This procedure generated approximately seven equivalents ofreducing activity. After extensive dialysis, the oxidized PS was Iyophilized. Adipic acid dihydrazide (ADH) was introduced into the toxin A molecule by the use of carbodiimide (1 1, 14) . Approximately 13 mol of ADH were incorporated into each mole of toxin A as determined by reaction with 2,4,6-trinitrobenzenesulfonic acid (TNBS) using ADH to generate a standard curve. Toxin A-ADH was covalently coupled to oxidized PS by mixing equal amounts at 22°C for 6 h. At this time, NaCNBH3 was added to reduce Schiffs bases and the mixture stored at 22°C for 5 d. The mixture was then extensively dialyzed against phosphate-buffered saline (PBS) and filtered over an AcA34 column equilibrated in PBS. The conjugate contained no detectable reactive hydrazide groups as determined by reaction with TNBS. Collected fractions were analyzed by measuring the absorbance at 220 and 280 nm, respectively. The material that eluted in the void volume ofthe column (Mr > 350,000) was pooled and lyophilized.
Analytical methods. The protein content of the conjugate was measured by the method of Lowry et al. (15) using toxin A as a standard. The carbohydrate content was determined by the tryptophane reaction (16) using purified P. aeruginosa PS as a standard.
Enzymatic activity assay. The adenosine diphosphateribosyl (ADPRtransferase activity oftoxin A was measured as previously described after activation in the presence of urea and dithiothreitol (17 Enzyme-linked immunosorbent assays (ELISA). ELISA for the quantitation of anti-toxin A and anti-LPS IgG were performed as previously described (1 1, 13). The conjugate used was peroxidase-labeled protein A produced by the method of Nakane and Kawaoi (18) . Color was allowed to develop for 10 min after the addition of the substrate solution ( 11) and read at 405 nm on a Titertek Multiscan (Flow Laboratories, Hamden, CT).
A standard curve for the quantitation of IgG was produced as follows. Affinity purified goat anti-human IgG (Kirkegaard and Perry, Gaithersburg, MD) was diluted in PBS (10 ug/ml) and 200 Ml added to each well of a flat-bottomed microtiter plate. The plates were incubated for 3 h at 37°C and then stored at 4°C until used. After three washes with PBS containing 0.02% Tween-20 (PBS-T), 200 Ml of purified human IgG (Globuman, Swiss Serum and Vaccine Institute, Berne, Switzerland) from 0.009 Mg/ml to 10 Mg/ml in twofold serial dilutions were added per well.
The plates were then processed in the same manner as described above. When the results were plotted as the absorbance at 405 nm versus the log of IgG concentration, the linear portion of the curve was found between 0.03 and 0.7 ,g IgG/ml. Human IgG was excluded from control wells.
Specific IgG antibody to LPS or toxin A in human serum was derived as follows. A dilution of each test serum giving an absorbance within the linear region ofthe standard curve was used to calculate micrograms of IgG. This value was then multiplied by the dilution factor to yield micrograms IgG/ml of serum.
Opsonophagocytosis assay. Opsonophagocytic assays were performed as previously described ( 19) .
Column chromatography. The conjugate vaccine was sized by gel filtration over Sephacryl S-500. The column (1 cm X 45 cm) was equil- Vaccine. Conjugate-containing fractions that eluted in the void volume of an AcA34 column (see above) were pooled and the protein and carbohydrate content determined. The conjugate was diluted in an equal volume of 10% (wt/vol) lactose. This was further diluted in 5% (wt/vol) lactose in PBS to yield a final conjugate concentration of 100 Mg carbohydrate and 225 Mg protein/ml. This was passed through a 0.45-Mm filter under aseptic conditions. The vaccine (1 ml) was placed in sterile glass vials and lyophilized under asceptic conditions. The vials were labeled, sealed, and stored at 40C.
Tests for sterility and general safety of the vaccine were performed according to requirements set forth under articles V.2. 1.1 and V.2.1.5 of the European Pharmacopoeia (20) . Pyrogenicity testing was performed in New Zealand white rabbits as previously described (21) .
Subjects and study design. Healthy volunteers of both sexes aged pyrogenic when tested at a dose of 50 ,g/kg and nontoxic upon intraperitoneal administration to mice and guinea pigs. To document that the vaccine was not subject to toxic reversion when exposed to physiologic temperatures, the following experiments were performed. Reconstituted vaccine was incubated at 370C for 28 d at which time 200 Mg of conjugate protein (equivalent to 1,000 mean lethal doses for native toxin A protein) was injected intraperitoneally into mice. No overt signs of illness were observed and all mice survived. Similarly, there was no evidence of an increase in enzymatic activity after storage.
The above results, demonstrating the safety and stability of the conjugate vaccine, led us to evaluate its acceptability and immunogenicity in humans. Healthy adult volunteers received either 162. Table II . Only a single vaccinee noted a local reaction after the first vaccination.
One subject experienced malaise 24 h postimmunization that 52 Cryz, Farer, Cross, Wegmann, Germanier, and Sadoff Antibody directed against the O-PS moiety of the conjugate vaccine was capable of promoting the phagocytosis and killing of an IT-5 strain of P. aeruginosa by human polymorphonuclear leukocytes (Table V) . Both immunizing doses were found to be equally effective at engendering an opsonic antibody response. The postimmune mean titer was comparable in both groups, as were the number of individuals responding with a significant (more than fourfold) rise in titer. All but one volunteer, who received the low vaccine dose, made a significant response.
The ability of antibody evoked following immunization with the conjugate vaccine to afford protection against fatal experimental P. aeruginosa immunotype 5 burn wound sepsis is shown in Table VI . Compared with mice that received human albumin, both preimmune and postimmune IgG were able to increase the LD50. The level of protection was dependent upon the amount of specific antibody transferred. Therefore, while preimmune IgG raised the LD50 value 14-fold over the human albumin-treated group, the administration of postimmune IgG with -10-fold higher antibody content resulted in a further 100-fold increase. To confirm that protection was indeed me- diated by anti-conjugate antibody, postimmune IgG was absorbed with the conjugate vaccine. This procedure, which reduced the levels ofantitoxin A and anti-LPS antibody to slightly below those for preimmune IgG, resulted in a corresponding loss in protective capacity. It is interesting to note that submicrogram amounts of specific antibody could confer an extremely high degree of protection in this model system. To determine the relative protective roles ofantitoxin A versus anti-LPS antibody in this model system, the following experiment was performed. Groups of mice received either preimmune or postimmune IgG before burning and challenge with a toxin A-producing strain of a heterologous LPS immunotype (immunotype 1). The LD50 value for both groups was identical (2 X 103) indicating that the protection noted above was mediated primarily by anti-LPS antibody. These findings are in agreement with previously published studies showing that antitoxin A antibody is poorly protective in this model system against highly virulent challenge strains (13).
Discussion
The need for immunological agents to aid in the control of P. aeruginosa infections is documented by the fact that mortality rates for nosocomial bacteremic episodes have remained essentially unchanged for the past three decades (4, 5) . Immunoprophylactic or immunotherapeutic intervention is complicated by the fact that various patient populations are at risk to acquiring $Preimmune = prior to vaccination (day 0). Postimmune = 2 wk after receiving the second immunization (day 42). a life-threatening P. aeruginosa infection (4, 6) . Therefore, the mode in which a P. aeruginosa vaccine is employed would depend upon the immune status of the individual. Active vaccination is a feasible approach in certain high-risk groups, such as in burned or surgical patients who have been shown to mount a good humoral immune response to parenterally administered P. aeruginosa antigens (10, 25, 26) . Immunosuppressed patients, on the other hand, would not be expected to benefit greatly from immunization due to their depressed capacity to mount an antibody response (9, 27, 28) . In such cases, a hyperimmune gammaglobulin for intravenous use produced from the plasma of immunized donors would be the most logical approach.
Promising, but inconclusive results from clinical trials using a polyvalent LPS vaccine suggest that an immunological approach against P. aeruginosa infections is possible (10) . Supporting this hypothesis is the finding that elevated levels of antibody to LPS and toxin A have been found to correlate with survival from P. aeruginosa bacteremia and may act in an independent and additive manner (7, 8) . This would indicate that optimal protection against P. aeruginosa would be obtained by use ofa vaccine capable ofeliciting both anti-LPS and anti-toxin A antibody. We have, therefore, selected toxin A to serve as the carrier protein for nonimmunogenic serospecific O-PS in the construction of a conjugate to meet these requirements.
The O-PS-toxin A conjugate vaccine presently described was found to be safe when parenterally administered to healthy adult volunteers. No systemic reactions of consequence (fever, chills, etc.) were noted and local reactions were infrequent and mild in nature. No significant abnormalities in blood chemistry or serum liver enzyme levels were seen following vaccination. This is particularly important because the liver is the target organ for toxin A (29, 30) . It would appear that the covalent coupling of ADH to toxin A, which destroys the enzymatic activity of the molecule by which toxicity is mediated, results in a detoxified protein not subject to in vivo reversion. Immunization with the conjugate engendered both anti-toxin IgG and anti-LPS IgG antibody. The mean level of anti-toxin A IgG induced by immunization (9.4 and 29.0 ,g/ml at the 25-and 50-gg doses, respectively) were comparable to those measured in patients who survived a bacteremic episode with a toxin A-producing strain ofP. aeruginosa (25.8 ,ug/ml) (7) . Similarly, the concentration ofanti-LPS found in the serum ofvaccinated individuals (30 and 32 gg/ml at the 25-and 50-gg doses, respectively) was also comparable to levels obtained by survivors ofP. aeruginosa bacteremia (12.8 pg/ml) (31) . Ofperhaps greater significance was the finding that both anti-LPS and antitoxic antibody possessed the desired functional attributes. Therefore, anti-toxin A antibody was capable of neutralizing the cytotoxic activity of toxin A while anti-LPS antibody was opsonic. Furthermore, human antibody directed against the conjugate was highly protective against fatal P. aeruginosa infection when evaluated in a murine burn sepsis model.
The O-PS-toxin A conjugate vaccine described herein possesses those characteristics desired of a P. aeruginosa vaccine; it was safe upon parenteral administration to humans, stable, and capable of evoking high levels of antibody to both toxin A and LPS, which exhibited the necessary functional attributes essential for protection against infection. Since the highest survival rate following P. aeruginosa bacteremia was found among patients with elevated levels of antibody to both toxin A and LPS (8) , the currently described vaccine may prove to be more efficacious than other P. aeruginosa candidate vaccines capable of engendering an immune response to only one P. aeruginosa antigen (6, 16, 32, 33) .
Prior seroepidemiological surveys have noted that several serotypes of P. aeruginosa can be responsible for life-threatening infections (6, 32) . Therefore, any vaccine using serospecific antigen would have to be multivalent. It is presently envisioned that such a polyvalent conjugate vaccine would be composed of the appropriate serotypes of O-PS coupled to toxin A. However, due to the considerable heterogeneity in the monosaccharide composition of O-PS between serotypes (34, 35) , it remains to be seen ifthe conjugation strategy currently used can be applied with comparable results to other relevant O-PS antigens.
